Published in Lancet on November 10, 1984
Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci U S A (1992) 2.56
Kawasaki disease: recent advances. Arch Dis Child (1991) 2.30
Management of Kawasaki disease. Arch Dis Child (2013) 2.30
Management of Kawasaki disease in the British Isles. Arch Dis Child (1993) 1.79
Advances in Kawasaki disease. Eur J Pediatr (2004) 1.66
Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ Cardiovasc Genet (2012) 1.65
Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr (2006) 1.61
Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One (2012) 1.45
Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest (1987) 1.45
Kawasaki disease in Australia, 1993-95. Arch Dis Child (1998) 1.42
Long term consequences of regressed coronary aneurysms after Kawasaki disease: vascular wall morphology and function. Heart (2000) 1.39
Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics (2010) 1.33
Kawasaki syndrome. Clin Microbiol Rev (1998) 1.28
Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol (2005) 1.21
Pathogenesis of Kawasaki disease. Clin Exp Immunol (2011) 1.18
Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med (1995) 1.17
Kawasaki disease. Yonsei Med J (2006) 1.16
Kawasaki disease in the adult: a case report and review of the literature. Tex Heart Inst J (2004) 1.16
Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. Clin Exp Immunol (2009) 1.16
Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease. J Immunol (2009) 1.07
Assessment of risk factors for Korean children with Kawasaki disease. Pediatr Cardiol (2011) 1.04
Intravenous immune globulin use in children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. CMAJ (1992) 1.02
Human intravenous immunoglobulin modulates monokine production in vitro. Immunology (1990) 1.02
Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system". Yonsei Med J (2012) 1.01
Clinical aspects of 100 patients with Kawasaki disease. Arch Dis Child (1991) 0.99
Increased incidence of incomplete Kawasaki disease at a pediatric hospital after publication of the 2004 American Heart Association guidelines. Pediatr Cardiol (2012) 0.95
Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. J Clin Immunol (2005) 0.94
Mononuclear cell subsets and coronary artery lesions in Kawasaki disease. Arch Dis Child (1992) 0.94
Delayed apoptosis of circulating neutrophils in Kawasaki disease. Clin Exp Immunol (2001) 0.92
Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J (2008) 0.91
Acute Kawasaki disease: not just for kids. J Gen Intern Med (2007) 0.91
Antiendothelial cell antibodies detected by a cellular based ELISA in Kawasaki disease. Arch Dis Child (1991) 0.90
Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr (2008) 0.90
Kawasaki disease as a systemic vasculitis in childhood. Ann Vasc Dis (2010) 0.89
Epidemiologic features and prognostic factors of coronary artery lesions associated with Kawasaki disease based on a 13-year cohort of consecutive cases identified by complete enumeration surveys in Wakayama, Japan. J Epidemiol (2014) 0.89
Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study. Pediatr Cardiol (2012) 0.89
Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe. Front Immunol (2014) 0.88
High dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child (1994) 0.88
Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.88
Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki disease. Clin Exp Immunol (1994) 0.87
Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease. Yonsei Med J (2014) 0.86
Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome. Int J Mol Sci (2016) 0.85
Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD). Clin Exp Immunol (1998) 0.84
Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med (2013) 0.84
Regulation of the expression of Fc gamma receptor on circulating neutrophils and monocytes in Kawasaki disease. Clin Exp Immunol (1999) 0.84
Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol (2015) 0.84
Inflammatory processes in Kawasaki disease reach their peak at the sixth day of fever onset: laboratory profiles according to duration of fever. J Korean Med Sci (2004) 0.83
Expression of IL-8 in Kawasaki disease. Clin Exp Immunol (2000) 0.82
History of Kawasaki disease. Clin Exp Nephrol (2014) 0.82
Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. Arch Dis Child (1995) 0.82
Effectiveness of Medium-Dose Intravenous Immunoglobulin (1 g/kg) in the Treatment of Kawasaki Disease. Korean Circ J (2010) 0.82
Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ (2015) 0.81
Kawasaki disease. Proc Jpn Acad Ser B Phys Biol Sci (2006) 0.80
Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.80
Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.80
Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway. Clin Exp Immunol (2002) 0.80
Treatment of vasculitis. Br J Clin Pharmacol (1993) 0.80
An atypical case of a 2-year-old boy with acute kidney injury: a race against time. Answers. Pediatr Nephrol (2016) 0.79
Elevated Serum Levels of IL-21 in Kawasaki Disease. Allergy Asthma Immunol Res (2012) 0.79
DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease. Pediatr Rheumatol Online J (2013) 0.79
Investigations of selected historically important syndromic outbreaks: impact and lessons learned for public health preparedness and response. Am J Public Health (2012) 0.79
Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med (2013) 0.78
Stimulation of the respiratory burst and promotion of bacterial killing in human granulocytes by intravenous immunoglobulin preparations. Clin Exp Immunol (1990) 0.78
Affects of "age at diagnosis" on coronary artery lesions in patients with incomplete kawasaki disease. Korean Circ J (2010) 0.78
Natriuretic Peptides in Kawasaki Disease: the Myocardial Perspective. Diagnostics (Basel) (2013) 0.78
Use of corticosteroids during acute phase of Kawasaki disease. World J Clin Pediatr (2015) 0.77
Decreasing fertility rate correlates with the chronological increase and geographical variation in incidence of Kawasaki disease in Japan. PLoS One (2013) 0.77
Kawasaki syndrome: lessons for Britain. BMJ (1990) 0.77
Regulation of oxidative stress in patients with Kawasaki disease. Inflammation (2012) 0.76
GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. J Exp Med (2016) 0.76
Arthritis in Kawasaki disease after responding to intravenous immunoglobulin treatment. Eur J Pediatr (2005) 0.76
Kawasaki disease for dermatologists. Indian Dermatol Online J (2016) 0.76
Predicting the characteristics of the aetiological agent for Kawasaki disease from other paediatric infectious diseases in Japan. Epidemiol Infect (2015) 0.75
Intravenous gammaglobulin for immunodeficiency: report from The European Group for Immunodeficiencies (EGID). Clin Exp Immunol (1986) 0.75
From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies. Clin Exp Immunol (2001) 0.75
Late development of coronary artery abnormalities could be associated with persistence of non-fever symptoms in Kawasaki disease. Pediatr Rheumatol Online J (2013) 0.75
Clinical immunology. Postgrad Med J (1991) 0.75
Incomplete, atypical kawasaki disease or evolving systemic juvenile idiopathic arthritis: a case report. Cases J (2009) 0.75
Nephrology, dialysis and transplantation. Postgrad Med J (1993) 0.75
Relationship between gallbladder distension and lipid profiles in kawasaki disease. Korean Circ J (2010) 0.75
Kawasaki disease at British Columbia's Children's Hospital. Paediatr Child Health (2004) 0.75
Patterns of Carotid Intima-Media Thickness Progression in Kawasaki Patients: A Crystal Ball for Long-Term Vascular Health? J Am Heart Assoc (2016) 0.75
Chronic demyelinating polyneuropathy associated with eosinophilia-myalgia syndrome. J Neurol Neurosurg Psychiatry (1992) 0.75
Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. Curr Ther Res Clin Exp (2003) 0.75
Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders. J Neurol (2006) 0.75
Low-dose antithrombotic treatment in coronary thrombosis of Kawasaki disease. Pediatr Cardiol (2014) 0.75
Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med (1999) 6.09
Purification to homogeneity and properties of two D-alanine carboxypeptidases I From Escherichia coli. J Biol Chem (1976) 4.66
Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature (1992) 4.43
Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun (1989) 4.24
ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell (1998) 3.98
The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J (2000) 3.83
Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos. Nature (1996) 3.79
Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med (1995) 3.74
The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer (1999) 3.47
Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background. J Am Coll Cardiol (1999) 3.38
SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem (2000) 3.20
Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother (1991) 3.05
Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med (1996) 2.95
The effect of zinc supplementation on pregnancy outcome. JAMA (1995) 2.87
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Unmasking of latent hypoparathyroidism in a child with partial DiGeorge syndrome by ethylenediaminetetraacetic acid infusion. Eur J Pediatr (1993) 2.69
Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest (1993) 2.52
Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. World J Surg (2000) 2.51
Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J Biol Chem (2001) 2.50
Primary structure of heat-labile enterotoxin produced by Escherichia coli pathogenic for humans. J Biol Chem (1984) 2.48
PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet (1997) 2.44
Ampulla cardiomyopathy ('Takotusbo' cardiomyopathy)--reversible left ventricular dysfunction: with ST segment elevation. Jpn Circ J (2000) 2.39
Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest (2000) 2.39
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene (2006) 2.37
Conserved left-right asymmetry of nodal expression and alterations in murine situs inversus. Nature (1996) 2.35
Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood (2000) 2.30
Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet (1986) 2.29
Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. J Neurosurg (1990) 2.28
Folic acid safety and toxicity: a brief review. Am J Clin Nutr (1989) 2.17
The natural history of herniated nucleus pulposus with radiculopathy. Spine (Phila Pa 1976) (1996) 2.16
Inhibition of protein kinase C by calphostin C is light-dependent. Biochem Biophys Res Commun (1991) 2.16
In vitro peptidoglycan polymerization catalysed by penicillin binding protein 1b of Escherichia coli K-12. FEBS Lett (1980) 2.14
Immunosuppression, liver injury, and hepatitis in renal, hepatic, and cardiac homograft recipients: with particular reference to the Australia antigen. Ann Surg (1971) 2.14
The reduced expression of 6Ckine in the plt mouse results from the deletion of one of two 6Ckine genes. J Exp Med (1999) 2.14
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol (2009) 2.14
Prions prevent neuronal cell-line death. Nature (1999) 2.13
Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun (1989) 2.13
Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics (1979) 2.08
Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. Anesthesiology (1992) 2.07
Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem (1994) 2.06
Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci U S A (1999) 2.04
Telomerase activity in gastric cancer. Cancer Res (1995) 2.02
Distinct but overlapping roles of histone acetylase PCAF and of the closely related PCAF-B/GCN5 in mouse embryogenesis. Proc Natl Acad Sci U S A (2000) 1.99
Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun (1995) 1.97
Dilution is effective in reducing infusion phlebitis in peripheral parenteral nutrition: an experimental study in rabbits. Nutrition (1998) 1.96
Photoplethysmography. Part 1. Comparison with laser Doppler flowmetry. Med Biol Eng Comput (1991) 1.92
Electron flow to oxygen in higher plants and algae: rates and control of direct photoreduction (Mehler reaction) and rubisco oxygenase. Philos Trans R Soc Lond B Biol Sci (2000) 1.92
Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosa iodine staining. Cancer (1995) 1.91
Antibodies against synthetic peptides as a tool for functional analysis of the transforming protein pp60src. Cell (1983) 1.91
Mice lacking expression of the chemokines CCL21-ser and CCL19 (plt mice) demonstrate delayed but enhanced T cell immune responses. J Exp Med (2001) 1.90
Cloning of inv, a gene that controls left/right asymmetry and kidney development. Nature (1998) 1.90
Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes. Proc Natl Acad Sci U S A (1984) 1.89
Genomic structure of the murine IL-6 gene. High degree conservation of potential regulatory sequences between mouse and human. J Immunol (1988) 1.86
Role of adapter function in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma. J Biol Chem (1999) 1.82
Plasmodium berghei infection in mice induces liver injury by an IL-12- and toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J Immunol (2001) 1.82
Self-organization mechanism in a bone-like hydroxyapatite/collagen nanocomposite synthesized in vitro and its biological reaction in vivo. Biomaterials (2001) 1.81
Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes. Eur J Immunol (1997) 1.81
The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology (1999) 1.79
Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients. Ann Thorac Surg (1999) 1.79
Cross-cultural comparison of the sleep-disordered breathing prevalence among Americans and Japanese. Eur Respir J (2010) 1.79
Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology (1998) 1.75
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol (2003) 1.75
Ecology of Vibrio cholerae non-O1 and Salmonella spp. and role of zooplankton in their seasonal distribution in Fukuyama coastal waters, Japan. Appl Environ Microbiol (1989) 1.74
Characterization of adipose tissue-derived cells isolated with the Celution system. Cytotherapy (2008) 1.73
Light adaptation in retinal rods of the rabbit and two other nonprimate mammals. J Gen Physiol (1991) 1.73
On the process of cellular division in Escherichia coli: isolation and characterization of penicillin-binding proteins 1a, 1b, and 3. Proc Natl Acad Sci U S A (1980) 1.73
Telomerase activity in human breast tumors. J Natl Cancer Inst (1996) 1.73
Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer (1999) 1.72
Self-compartmentalizing proteases. Trends Biochem Sci (1997) 1.71
Preparation and characterization of a mouse osteoclast-like multinucleated cell population. J Bone Miner Res (1992) 1.71
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst (1991) 1.70
Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis (1998) 1.70
"Transmural air leak": a computed tomographic finding following endoscopic submucosal dissection of gastric tumors. Endoscopy (2010) 1.69
Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity (1999) 1.67
Post-translational glycosylation of coronavirus glycoprotein E1: inhibition by monensin. EMBO J (1982) 1.67
Lumbar nerve root compression caused by lumbar intraspinal gas. Report of three cases. Spine (Phila Pa 1976) (1997) 1.65
Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology (N Y) (1990) 1.64
CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem (1998) 1.64
Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-alpha. J Mol Cell Cardiol (2001) 1.63
Is intrapartum temporary pacing required for women with complete atrioventricular block? An analysis of seven cases. BJOG (2006) 1.62
Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. J Pediatr (1980) 1.62
Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol (2001) 1.62
Homeobox protein Hex induces SMemb/nonmuscle myosin heavy chain-B gene expression through the cAMP-responsive element. Circ Res (2001) 1.61
Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med (1995) 1.60
Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem (1997) 1.60
Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones. Mol Endocrinol (1999) 1.58
Prevention of pulmonary embolism by a foot sole pump. J Bone Joint Surg Br (2001) 1.57
Mice devoid of the glial fibrillary acidic protein develop normally and are susceptible to scrapie prions. Neuron (1995) 1.57
Effects of erythorbic acid on vitamin C metabolism in young women. Am J Clin Nutr (1996) 1.55
Noninvasive urodynamic evaluation of bladder outlet obstruction using Doppler ultrasonography. Urology (2000) 1.54
PCR detection of distal Yp sequences in an XX true hermaphrodite. Am J Med Genet (1991) 1.54
Molecular basis for hematopoietic/mesenchymal interaction during initiation of Peyer's patch organogenesis. J Exp Med (2001) 1.53
Characterization of guanylate cyclase activity in single retinal rod outer segments. J Gen Physiol (1995) 1.53
DiGeorge syndrome with hypogammaglobulinaemia: a patient with excess suppressor T cell activity treated with fetal thymus transplantation. Eur J Pediatr (1989) 1.53
Butyrolactone autoregulator receptor protein (BarA) as a transcriptional regulator in Streptomyces virginiae. J Bacteriol (1997) 1.52